ReviewBiochemia medica2026
Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography.
Review in Biochemia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with chronic total occlusion on coronary angiography, myocardial viability assessment is an essential tool in guiding treatment decisions, especially revascularization. Current non-invasive tests are often limited by the presence of myocardial fibrosis. This narrative review incorporates evidence from 76 studies and aims to provide an updated overview of non-invasive methods for myocardial viability assessment, with emphasis on the role of myocardial fibrosis. Every imaging modality provides valuable information, even though they differ in sensitivity, specificity, availability, radiation exposure, contraindications and limitations in the presence of fibrosis. Biomarkers that provide insight into different aspects of myocardial fibrosis - including collagen synthesis (procollagen type I carboxy-terminal propeptide and procollagen type III amino-terminal propeptide), as well as inflammation and fibrotic signalling (galectin-3) - may complement imaging by reflecting myocardial remodelling. However, main limitations to this approach are no standardized reference ranges and cut-off values, analytical variability and insufficient validation for clinical outcomes prediction. Despite their potential to guide personalized revascularization decisions, circulating fibrosis biomarkers currently remain experimental tools. Further large-scale prospective clinical studies that incorporate biomarkers with imaging are needed before their implementation into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.